{"id":9113,"date":"2019-05-17T14:45:00","date_gmt":"2019-05-17T12:45:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/"},"modified":"2019-05-17T14:45:00","modified_gmt":"2019-05-17T12:45:00","slug":"irlab-genomfor-aktiesplit","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-genomfor-aktiesplit\/","title":{"rendered":"IRLAB genomf\u00f6r aktiesplit"},"content":{"rendered":"<p>[mfn_before_post]<\/p>\n<div class=\"mfn-preamble\"><strong>Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.<\/strong><\/div>\n<p><span>Sista dag f\u00f6r handel med aktier f\u00f6re uppdelningen \u00e4r m\u00e5ndagen den 27 maj 2019 och f\u00f6rsta dag f\u00f6r handel med aktier efter uppdelningen \u00e4r tisdagen den 28 maj 2019. Detta inneb\u00e4r att aktiekursen kommer att \u00e5terspegla effekten av uppdelningen fr\u00e5n och med den 28 maj 2019.<\/span><\/p>\n<p><span>Avst\u00e4mningsdagen f\u00f6r genomf\u00f6rande av uppdelningen infaller onsdagen den 29 maj 2019 och aktierna som erh\u00e5lls genom uppdelningen ber\u00e4knas registreras p\u00e5 aktie\u00e4garnas konton fredagen den 31 maj 2019 vilket \u00e4r den f\u00f6rsta bankdagen efter avst\u00e4mningsdagen.<\/span><\/p>\n<p><span>Den nya ISIN-koden kommer att vara SE0012675361 f\u00f6r aktierna av Serie A och<\/span> <span>SE0012675379 f\u00f6r aktierna av Serie B.<\/span><\/p>\n<p><span>Genom uppdelningen kommer antalet aktier i bolaget att \u00f6ka fr\u00e5n sammanlagt 8\u00a0099\u00a0939, varav 8\u00a0028\u00a0388 aktier av Serie A och 71\u00a0551 aktier av Serie B, till sammanlagt 40\u00a0499\u00a0695, varav 40\u00a0141\u00a0940 aktier av Serie A och 357\u00a0755 aktier av Serie B. Villkoren f\u00f6r konvertering av aktier av Serie B till aktier av Serie A samt villkoren f\u00f6r utest\u00e5ende teckningsoptioner har som en f\u00f6ljd av uppdelningen omr\u00e4knats i enlighet med villkoren.<\/span><\/p>\n<p><span>Uppdelningen av bolagets aktier sker automatiskt via Euroclear Sweden AB och aktie\u00e4gare beh\u00f6ver inte vidta n\u00e5gra \u00e5tg\u00e4rder.<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><strong>F\u00f6r vidare information<\/strong><\/p>\n<p>Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0<br \/>E-post: <a href=\"mailto:nicholas.waters@irlab.se\" rel=\"nofollow\">nicholas.waters@irlab.se<\/a><\/p>\n<p>Viktor Siewertz, CFO\u00a0<br \/>Tel: +46 727 10 70 70\u00a0<br \/>E-post: <a href=\"mailto:viktor.siewertz@irlab.se\" rel=\"nofollow\">viktor.siewertz@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong>Om IRLAB<\/strong><\/p>\n<p>IRLAB \u00e4r ett svenskt biotechbolag fokuserat p\u00e5 Parkinsons sjukdom. Bolagets kliniska Fas II-kandidater, IRL752 och IRL790, \u00e4mnar behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinsons sjukdom: ofrivilliga r\u00f6relser (LIDs), psykos och demens. Genom den propriet\u00e4ra forskningsplattformen ISP (Integrative Screening Process) uppt\u00e4cker och utvecklar IRLAB l\u00e4kemedelskandidater f\u00f6r sjukdomar relaterade till det centrala nervsystemet (CNS) d\u00e4r stora v\u00e4xande medicinska behov f\u00f6religger. F\u00f6rutom de kliniska kandidaterna har ISP-plattformen dessutom genererat flera CNS-program som nu \u00e4r i preklinisk fas. IRLAB:s Certified Adviser p\u00e5 Nasdaq First North \u00e4r FNCA Sweden AB, info@fnca.se, 08-528 00 399. Mer information p\u00e5 <a href=\"http:\/\/www.irlab.se\/\" rel=\"nofollow\">www.irlab.se<\/a>.<\/p>\n<\/div>\n<p>[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.<\/p>\n","protected":false},"template":"","class_list":["post-9113","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca-shares_sv","mfn-news-tag-mfn-ca_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-lhfi_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ca-shares-rights_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB genomf\u00f6r aktiesplit - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB genomf\u00f6r aktiesplit - IRLAB\" \/>\n<meta property=\"og:description\" content=\"Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/\",\"name\":\"IRLAB genomf\u00f6r aktiesplit - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2019-05-17T12:45:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB genomf\u00f6r aktiesplit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB genomf\u00f6r aktiesplit - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB genomf\u00f6r aktiesplit - IRLAB","og_description":"Vid IRLAB Therapeutics AB:s \u00e5rsst\u00e4mma den 25 april 2019 beslutades om en uppdelning av bolagets aktie, en s\u00e5 kallad aktiesplit. De beslutade villkoren f\u00f6r aktiespliten \u00e4r en 5:1 uppdelning, d\u00e4r varje nuvarande aktie (1) delas upp i fem (5) aktier av samma slag. Datum f\u00f6r genomf\u00f6randet av uppdelningen har nu fastst\u00e4llts.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/","name":"IRLAB genomf\u00f6r aktiesplit - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2019-05-17T12:45:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-genomfor-aktiesplit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB genomf\u00f6r aktiesplit"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}